AIT Therapeutics Stock Price, News & Analysis (OTCMKTS:AITB)

$3.85 -0.15 (-3.75 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$3.85
Today's Range$3.85 - $4.00
52-Week Range$3.51 - $10.00
Volume2,125 shs
Average Volume1,877 shs
Market Capitalization$24.39 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About AIT Therapeutics (OTCMKTS:AITB)

AIT Therapeutics logoAIT Therapeutics, Inc., formerly KokiCare, Inc., is a shell company. The Company is engaged in the discovery and planning phase to develop a real-time, software as a service (SaaS)-based enterprise software application to manage the integration, planning, tracking and management of healthcare assets, which include people, supplies, clinical data, relationships and financial resources of healthcare organizations. The Company seeks to develop health care enterprise software to be sold to hospitals, medical centers and health care facilities in the United States and internationally. As of September 30, 2016, the Company had not generated any revenues.

Receive AITB News and Ratings via Email

Sign-up to receive the latest news and ratings for AITB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:AITB
CUSIPN/A
Phone972-8684-3313

Debt

Debt-to-Equity RatioN/A
Current Ratio3.46%
Quick Ratio3.46%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net Income$-3,720,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-402.61%

Miscellaneous

Employees1
Outstanding Shares6,100,000

AIT Therapeutics (OTCMKTS:AITB) Frequently Asked Questions

What is AIT Therapeutics' stock symbol?

AIT Therapeutics trades on the OTCMKTS under the ticker symbol "AITB."

Where is AIT Therapeutics' stock going? Where will AIT Therapeutics' stock price be in 2018?

3 brokers have issued 1-year price objectives for AIT Therapeutics' stock. Their predictions range from $16.00 to $16.00. On average, they expect AIT Therapeutics' share price to reach $16.00 in the next year. View Analyst Ratings for AIT Therapeutics.

Who are some of AIT Therapeutics' key competitors?

Who are AIT Therapeutics' key executives?

AIT Therapeutics' management team includes the folowing people:

  • Ron Bentsur, Executive Chairman of the Board (Age 51)
  • Amir Avniel, President, Chief Operating Officer, Director (Age 44)
  • Steven A. Lisi, Chief Executive Officer, Director (Age 46)
  • Haim Aviv, Chief Financial Officer (Age 35)
  • Yossef Av-Gay Ph.D., Chief Scientific Officer (Age 54)
  • David Grossman, Director (Age 42)
  • Erick J. Lucera, Director
  • Ari Raved, Director (Age 64)
  • Lee Yoori, Director

How do I buy AIT Therapeutics stock?

Shares of AIT Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AIT Therapeutics' stock price today?

One share of AIT Therapeutics stock can currently be purchased for approximately $3.85.

How big of a company is AIT Therapeutics?

AIT Therapeutics has a market capitalization of $24.39 million. AIT Therapeutics employs 1 workers across the globe.

How can I contact AIT Therapeutics?

AIT Therapeutics' mailing address is 2 ILAN RAMON SCIENCE PARK, NESS ZIONA L3, 7403635. The company can be reached via phone at 972-8684-3313.


MarketBeat Community Rating for AIT Therapeutics (AITB)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  25 (Vote Outperform)
Underperform Votes:  29 (Vote Underperform)
Total Votes:  54
MarketBeat's community ratings are surveys of what our community members think about AIT Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AIT Therapeutics (OTCMKTS:AITB) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $16.00$16.00$15.00$16.00
Price Target Upside: 185.71% upside185.71% upside160.87% upside166.67% upside

AIT Therapeutics (OTCMKTS:AITB) Consensus Price Target History

Price Target History for AIT Therapeutics (OTCMKTS:AITB)

AIT Therapeutics (OTCMKTS:AITB) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
12/2/2017Roth CapitalSet Price TargetBuy$16.00View Rating Details
8/24/2017LaidlawInitiated CoverageBuy -> Buy$16.00View Rating Details
8/7/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuyView Rating Details
(Data available from 2/24/2016 forward)

Earnings

AIT Therapeutics (OTCMKTS:AITB) Earnings History and Estimates Chart

Earnings by Quarter for AIT Therapeutics (OTCMKTS:AITB)

AIT Therapeutics (OTCMKTS AITB) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/3/2017Q3 2017($0.59)($1.18)ViewN/AView Earnings Details
8/11/2017Q2 2017($0.46)ViewN/AView Earnings Details
5/15/2017Q1 2017($1.12)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

AIT Therapeutics (OTCMKTS:AITB) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.99 EPS
Next Year EPS Consensus Estimate: $-2 EPS

Dividends

Dividend History for AIT Therapeutics (OTCMKTS:AITB)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for AIT Therapeutics (OTCMKTS AITB)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

AIT Therapeutics (OTCMKTS AITB) News Headlines

Source:
DateHeadline
AIT Therapeutics Announces $9.82 Million Private PlacementAIT Therapeutics Announces $9.82 Million Private Placement
finance.yahoo.com - February 16 at 4:11 PM
AIT Therapeutics Announces Completion of the Agreement to License the Revolutionary Nitric Oxide (NO) Generator and Delivery SystemAIT Therapeutics Announces Completion of the Agreement to License the Revolutionary Nitric Oxide (NO) Generator and Delivery System
finance.yahoo.com - January 31 at 4:57 PM
Zacks Investment Research Downgrades AIT Therapeutics (AITB) to SellZacks Investment Research Downgrades AIT Therapeutics (AITB) to Sell
www.americanbankingnews.com - January 26 at 4:54 PM
AIT Therapeutics Announces Further Data From Its NO-NTM Abscessus Phase 2 Clinical Trial in Nontuberculous Mycobacteria (NTM) PatientsAIT Therapeutics Announces Further Data From Its NO-NTM Abscessus Phase 2 Clinical Trial in Nontuberculous Mycobacteria (NTM) Patients
finance.yahoo.com - January 22 at 5:26 PM
AIT Therapeutics (AITB) Upgraded at Zacks Investment ResearchAIT Therapeutics (AITB) Upgraded at Zacks Investment Research
www.americanbankingnews.com - January 2 at 6:46 PM
AIT Therapeutics Appoints Yoori Lee to its Board of DirectorsAIT Therapeutics Appoints Yoori Lee to its Board of Directors
feeds.benzinga.com - January 2 at 10:14 AM
AIT Therapeutics (AITB) Given a $16.00 Price Target at Roth CapitalAIT Therapeutics (AITB) Given a $16.00 Price Target at Roth Capital
www.americanbankingnews.com - December 3 at 10:46 AM
AIT Therapeutics Announces Publication of Its Phase 2 Trial in Bronchiolitis Patients in the Pediatric Pulmonology JournalAIT Therapeutics Announces Publication of Its Phase 2 Trial in Bronchiolitis Patients in the Pediatric Pulmonology Journal
finance.yahoo.com - December 1 at 4:16 PM
Compelling Preliminary Data on Key Secondary Endpoint of 6-Minute WalkCompelling Preliminary Data on Key Secondary Endpoint of 6-Minute Walk
globenewswire.com - November 28 at 11:26 AM
AIT Therapeutics, Inc. (AITB)AIT Therapeutics, Inc. (AITB)
finance.yahoo.com - November 28 at 11:26 AM
AIT Therapeutics Announces Positive Preliminary Data for the Primary Endpoint of Safety in Its NO-NTM Abscessus Phase 2 Clinical Trial in Nontuberculous Mycobacteria (NTM) PatientsAIT Therapeutics Announces Positive Preliminary Data for the Primary Endpoint of Safety in Its NO-NTM Abscessus Phase 2 Clinical Trial in Nontuberculous Mycobacteria (NTM) Patients
finance.yahoo.com - November 28 at 11:26 AM
AIT Therapeutics to Hold Clinical Update Meeting on November 28, 2017 at 7:30 a.m.AIT Therapeutics to Hold Clinical Update Meeting on November 28, 2017 at 7:30 a.m.
finance.yahoo.com - November 21 at 4:14 PM

SEC Filings

AIT Therapeutics (OTCMKTS:AITB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

AIT Therapeutics (OTCMKTS AITB) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.